ANRO Alto Neuroscience, Inc.
Healthcare$21.06-0.75%ClosedMarket Cap: $739.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.87
P/S
0.00
EV/EBITDA
-6.69
DCF Value
$5.91
FCF Yield
-8.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.2%
ROA
-26.9%
ROIC
20.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-27.1M | $-26.2M | $— | — |
| Q4 null | $0.00 | NaN% | $115.7M | $-16.2M | $— | — |
| FY null | $0.00 | -Infinity% | $-66.4M | $-63.2M | $— | — |
| Q3 null | $0.00 | NaN% | $-15.0M | $-14.2M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-18.7M | $-17.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-15.7M | $-15.2M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-17.0M | $-15.2M | $— | — |
| FY null | $0.00 | -Infinity% | $-68.6M | $-61.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-18.9M | $-16.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-18.3M | $-16.0M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-14.4M | $-13.4M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-11.8M | $-11.2M | $-0.42 | — |